Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.ipca.com | |
Market Cap | 22,663.40 Cr. | |
Enterprise Value(EV) | 22,267.69 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 19.36 | Trailing Twelve Months Ending 2023-06 |
Price-Earning Ratio (PE) | 46.24 | Trailing Twelve Months Ending 2023-06 |
Industry PE | 37.50 | Trailing Twelve Months Ending 2023-06 |
Book Value / Share | 236.82 | Trailing Twelve Months Ending 2023-06 |
Price to Book Value | 3.78 | Calculated using Price: 895.00 |
Dividend Yield | 0.45 | Period Ending 2023-03 |
No. of Shares Subscribed | 25.37 Cr. | 253,704,218 Shares |
FaceValue | 1 | |
About Ipca Laboratories Ltd. | ||
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. Ipca Laboratories is one of the largest suppliers of these APIs worldwide with manufacturing leadership in many APIs globally. It has various APIs and formulations manufacturing facility across the globe. The company has leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy in India |
1 Day |
|
-0.39% |
1 Week |
|
-3.79% |
1 Month |
|
+1.09% |
3 Month |
|
+22.70% |
6 Month |
|
+14.44% |
1 Year |
|
+2.02% |
2 Year |
|
-26.33% |
5 Year |
|
+152.27% |
10 Year |
|
+159.66% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 12.43 | 4.31 | 8.25 | 9.31 | 15.22 | 17.92 | 27.63 | 17.92 | 8.70 | |
Return on Capital Employed (%) | 13.78 | 4.82 | 9.18 | 9.81 | 16.48 | 19.71 | 30.92 | 20.46 | 11.71 | |
Return on Assets (%) | 7.38 | 2.50 | 4.96 | 5.93 | 10.21 | 12.31 | 20.29 | 13.31 | 6.06 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Shh. Funds | 1,960 | 2,208 | 2,259 | 2,455 | 2,689 | 3,122 | 3,627 | 4,702 | 5,465 | 5,842 | |
Non Curr. Liab. | 459 | 700 | 663 | 548 | 419 | 313 | 290 | 190 | 614 | 902 | |
Curr. Liab. | 791 | 904 | 970 | 956 | 1,008 | 1,098 | 1,326 | 1,161 | 1,466 | 1,806 | |
Minority Int. | 16 | 14 | 15 | 77 | 73 | ||||||
Equity & Liab. | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 | |
Non Curr. Assets | 1,609 | 2,198 | 2,270 | 2,218 | 2,170 | 2,171 | 2,402 | 2,629 | 3,164 | 3,434 | |
Curr. Assets | 1,601 | 1,614 | 1,622 | 1,742 | 1,945 | 2,378 | 2,856 | 3,437 | 4,457 | 5,189 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 3,211 | 3,812 | 3,892 | 3,960 | 4,116 | 4,549 | 5,258 | 6,066 | 7,622 | 8,623 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-06 Rs. Cr. TTM |
Net Sales | 3,144 | 2,867 | 3,156 | 3,258 | 3,746 | 4,619 | 5,395 | 5,797 | 6,204 | 6,246 | |
Other Income | 59 | 41 | 55 | 58 | 75 | 87 | 129 | 122 | 152 | 148 | |
Total Income | 3,203 | 2,908 | 3,211 | 3,316 | 3,820 | 4,706 | 5,524 | 5,918 | 6,356 | 6,395 | |
Total Expenditure | -2,630 | -2,593 | -2,741 | -2,816 | -3,067 | -3,729 | -3,914 | -4,539 | -5,301 | -5,281 | |
PBIDT | 573 | 314 | 470 | 500 | 753 | 977 | 1,610 | 1,379 | 1,055 | 1,114 | |
Interest | -32 | -35 | -27 | -28 | -22 | -20 | -12 | -11 | -48 | -70 | |
Depreciation | -180 | -163 | -173 | -178 | -182 | -211 | -209 | -232 | -262 | -269 | |
Taxation | -102 | -20 | -68 | -51 | -104 | -135 | -240 | -225 | -253 | -265 | |
Exceptional Items | |||||||||||
PAT | 259 | 96 | 195 | 239 | 442 | 604 | 1,149 | 911 | 492 | 510 | |
Minority Interest | 3 | 3 | -1 | -6 | -8 | -7 | |||||
Share Associate | -5 | -3 | -8 | -21 | -13 | -12 | |||||
Other Related Items | |||||||||||
Consolidated Net Profit | 254 | 93 | 195 | 239 | 446 | 606 | 1,140 | 884 | 471 | 491 | |
Adjusted EPS | 10 | 4 | 8 | 9 | 18 | 24 | 45 | 35 | 19 | 19 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 522 | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | |
Cash Fr. Inv. | -369 | -689 | -218 | -149 | -135 | -165 | -510 | -521 | -855 | -725 | |
Cash Fr. Finan. | -136 | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | 507 | |
Net Change | 17 | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 428 | 588 | |
Cash & Cash Eqvt | 74 | 104 | 169 | 143 | 218 | 371 | 295 | 559 | 991 | 1,579 |
Thu, 21 Sep 2023
Announcement under Regulation 30 (LODR)-Open Offer - Updates Further acquisition of 1 35 79 571 equity shares of Rs. 2/- each representing 19.29% of the paid-up share capital of Unichem Laboratories Ltd. under open offer. |
Mon, 18 Sep 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Compliance under Regulation 39(3) of the Securities and Exchange Board of India (LODR) Regulations 2015 |
Thu, 24 Aug 2023
USFDA Inspection Update Of Piparia Formulations Manufacturing Facility USFDA Inspection Update of Piparia formulations manufacturing facility |
Fri, 22 Sep 2023 |
|
|
|
|
|